Scribe Therapeutics Inc.
SCTX
IPO
$29.41
-$1.93-6.16%
NASDAQ
| 06/30/2026 | 03/31/2026 | 06/30/2025 | |||
|---|---|---|---|---|---|
| Revenue | 1.92M | 2.23M | 4.90M | ||
| Total Other Revenue | -- | -- | -- | ||
| Total Revenue | 1.92M | 2.23M | 4.90M | ||
| Cost of Revenue | 8.82M | 11.31M | 13.88M | ||
| Gross Profit | -6.91M | -9.07M | -8.99M | ||
| SG&A Expenses | 2.49M | 3.36M | 2.64M | ||
| Depreciation & Amortization | -- | -- | -- | ||
| Other Operating Expenses | -- | -- | -- | ||
| Total Operating Expenses | 11.31M | 14.66M | 16.53M | ||
| Operating Income | -9.40M | -12.43M | -11.63M | ||
| Income Before Tax | -6.27M | -17.12M | -10.62M | ||
| Income Tax Expenses | 212.00K | 228.00K | -712.00K | ||
| Earnings from Continuing Operations | -6.48M | -17.35M | -9.90M | ||
| Earnings from Discontinued Operations | -- | -- | -- | ||
| Extraordinary Item & Accounting Change | -- | -- | -- | ||
| Minority Interest in Earnings | -- | -- | -- | ||
| Net Income | -6.48M | -17.35M | -9.90M | ||
| EBIT | -9.40M | -12.43M | -11.63M | ||
| EBITDA | -8.75M | -11.79M | -10.91M | ||
| EPS Basic | -2.62 | -7.05 | -4.08 | ||
| Normalized Basic EPS | -2.34 | -3.18 | -2.92 | ||
| EPS Diluted | -2.62 | -7.05 | -4.08 | ||
| Normalized Diluted EPS | -2.34 | -3.18 | -2.92 | ||
| Average Basic Shares Outstanding | 2.48M | 2.46M | 2.43M | ||
| Average Diluted Shares Outstanding | 2.48M | 2.46M | 2.43M | ||
| Dividend Per Share | -- | -- | -- | ||
| Payout Ratio | -- | -- | -- | ||